Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?
Jan 12 2021
•
By
Mandy Jackson
Without CVR cash, Celgene investors still could see an additional payout via BMS share buybacks and long-term sales growth • Source: Shutterstock
More from New Products
More from Scrip